<?xml version="1.0" encoding="utf-8"?>
	<collection>
		
	
		<source>SourceData</source>
		
	
		<date>2019-04-19</date>
		
	
		<key>sourcedata.key</key>
		
	
		<document>
			
		
			<id>5167128 Figure_1-A</id>
			
		
			<infon key="sourcedata_document">2424</infon>
			
		
			<infon key="doi">10.15252/emmm.201506035</infon>
			
		
			<infon key="pmc_id">5167128</infon>
			
		
			<infon key="figure">Figure 1-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_1-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) Daily 10 μg 4-AP enhanced recovery of sciatic nerve motor function as compared with treatment with vehicle at 3 days post injury (dpi) through 8 dpi. (*: Day3 (D3), p= 0.0131; D5, p = 0.0475; D8, p =0.0472; n=6; ANOVA with post-hoc comparisons using two-tailed unpaired t-test)</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:sciatic</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="7" offset="43"/>
					
				
					<text>sciatic</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5167128 Figure_1-B</id>
			
		
			<infon key="sourcedata_document">2424</infon>
			
		
			<infon key="doi">10.15252/emmm.201506035</infon>
			
		
			<infon key="pmc_id">5167128</infon>
			
		
			<infon key="figure">Figure 1-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_1-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(B) Daily 10 μg 4-AP administration also enhanced recovery of nerve conduction velocity (NCV) as observed beginning at 21 days post-injury, eventually restoring NCV to near-normal values while NCV in vehicle-treated mice remained less than half that of uninjured animals (*: D21, p= 0.0454; D28, p = 0.0487; D35, p =0.0475; n=5; ANOVA with post-hoc comparisons using two-tailed unpaired t-test).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:velocity</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="8" offset="80"/>
					
				
					<text>velocity</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5167128 Figure_1-C-D</id>
			
		
			<infon key="sourcedata_document">2424</infon>
			
		
			<infon key="doi">10.15252/emmm.201506035</infon>
			
		
			<infon key="pmc_id">5167128</infon>
			
		
			<infon key="figure">Figure 1-C-D</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_1-C-D</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(C, D) Analysis of withdrawal latency in response to thermal (C) or mechanical (D) stimuli revealed that 4-AP treatment did not worsen these diagnostics of neuropathic pain syndromes. In the case of response to thermal hyperalgesis, 4-AP treated mice showed a significantly more rapid return to baseline levels. (*: (C) D3, D5, D8 : p&amp;lt;0.001 saline vs. baseline; D3 p= 0.006; 4-AP vs. baseline; (D) D3, p= 0.014; D5, p = 0.008; saline versus baseline; D3, p = 0.006 4-AP vs. baseline; D8: p =0.0472; n=10 ; ANOVA with post-hoc comparisons using two-tailed unpaired t-test.) In this and all other figures data is mean + SEM and shows a representative experiment from 2-3 repetitions.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:pain</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="4" offset="168"/>
					
				
					<text>pain</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5167128 Figure_2-A</id>
			
		
			<infon key="sourcedata_document">2424</infon>
			
		
			<infon key="doi">10.15252/emmm.201506035</infon>
			
		
			<infon key="pmc_id">5167128</infon>
			
		
			<infon key="figure">Figure 2-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_2-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) Local 4-AP treated crushed sciatic nerve (black: vehicle PLGA films; red: (4-AP)-PLGA films) regained partial walking ability as early as 3 days post-injury compared to vehicle treated group. (*: D5, p= 0.0004; D8, p = 0.0012; D11, p =0.003; D14, p=0.0089; n=6; ANOVA, with post-hoc comparisons using two-tailed unpaired t-test).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:films</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="5" offset="66"/>
					
				
					<text>films</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:films</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="5" offset="90"/>
					
				
					<text>films</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5167128 Figure_2-B</id>
			
		
			<infon key="sourcedata_document">2424</infon>
			
		
			<infon key="doi">10.15252/emmm.201506035</infon>
			
		
			<infon key="pmc_id">5167128</infon>
			
		
			<infon key="figure">Figure 2-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_2-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(B) Local 4-AP treated crushed sciatic nerve (black: vehicle PLGA films; red: (4-AP)-PLGA films) showed faster improvement in NCV restoration compared with vehicle-treated mice, beginning at 21 days post-injury.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:films</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="5" offset="66"/>
					
				
					<text>films</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:films</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="5" offset="90"/>
					
				
					<text>films</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5167128 Figure_3-A-B</id>
			
		
			<infon key="sourcedata_document">2424</infon>
			
		
			<infon key="doi">10.15252/emmm.201506035</infon>
			
		
			<infon key="pmc_id">5167128</infon>
			
		
			<infon key="figure">Figure 3-A-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_3-A-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) Electron microscopy images of healthy, crushed, and 4-AP treated crushed sciatic nerve at 21 days post-injury. Scale bar at 3000x = 5m; scale bar at 8000x = 2m) (B) Comparison of the axonal area of randomly chosen individual axons of vehicle treated and 4-AP treated mice (n=4 for each experimental group; 40 axons analyzed per mouse). 4-AP treated sciatic nerve showed statistically greater axonal area compared to the vehicle-treated group (p&amp;lt;0.05; ANOVA; restricted-maximum-likelihood). Moreover, 4-AP treated mice had a greater proportion of axons with areas greater than the mean value for uninjured mice (shown in the green line), with inset figure displaying all axons with values above this mean. This experiment represents a single group of mice of one of three replicates on NCV recovery.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:crushed</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="7" offset="43"/>
					
				
					<text>crushed</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:crushed</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="7" offset="69"/>
					
				
					<text>crushed</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5167128 Figure_4-A-B</id>
			
		
			<infon key="sourcedata_document">2424</infon>
			
		
			<infon key="doi">10.15252/emmm.201506035</infon>
			
		
			<infon key="pmc_id">5167128</infon>
			
		
			<infon key="figure">Figure 4-A-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-A-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A, B) Sustained local 4-AP administration was associated with increased myelin area and close-to-normal Garea-ratio compared to untreated group, as determined by analysis of 40 randomly chosen myelinated axons from sections of 4 nerves for each group. (**: p&amp;lt;0.0001; ANOVA, with post-hoc comparisons using two-tailed unpaired t-test). 4-AP treated mice had a greater proportion of axons for which the associated myelin area was greater than the mean value for uninjured mice (shown in the green line), with inset figure displaying all axons with values above this mean.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:myelinated</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="10" offset="194"/>
					
				
					<text>myelinated</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:myelin</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="6" offset="73"/>
					
				
					<text>myelin</text>
					
			
				</annotation>
				
			
				<annotation id="3">
					
				
					<infon key="type">protein:myelin</infon>
					
				
					<infon key="sourcedata_figure_annot_id">3</infon>
					
				
					<infon key="sourcedata_article_annot_id">3</infon>
					
				
					<location length="6" offset="413"/>
					
				
					<text>myelin</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5167128 Figure_4-C</id>
			
		
			<infon key="sourcedata_document">2424</infon>
			
		
			<infon key="doi">10.15252/emmm.201506035</infon>
			
		
			<infon key="pmc_id">5167128</infon>
			
		
			<infon key="figure">Figure 4-C</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-C</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(C, D) 4-AP treated nerves also showed increases in the levels of P0 protein as detected by western blot analysis (**:p&amp;lt;0.01; ANOVA, with post-hoc comparisons using two-tailed unpaired t-test).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5167128 Figure_4-D</id>
			
		
			<infon key="sourcedata_document">2424</infon>
			
		
			<infon key="doi">10.15252/emmm.201506035</infon>
			
		
			<infon key="pmc_id">5167128</infon>
			
		
			<infon key="figure">Figure 4-D</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-D</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(C, D) 4-AP treated nerves also showed increases in the levels of P0 protein as detected by western blot analysis (**:p&amp;lt;0.01; ANOVA, with post-hoc comparisons using two-tailed unpaired t-test).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5167128 Figure_4-E</id>
			
		
			<infon key="sourcedata_document">2424</infon>
			
		
			<infon key="doi">10.15252/emmm.201506035</infon>
			
		
			<infon key="pmc_id">5167128</infon>
			
		
			<infon key="figure">Figure 4-E</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-E</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(E) Increases in P0 protein over time also were observed by immunofluorescence analysis at different time points, with P0 protein expression increasing to a greater extent in nerves of mice treated with 4-AP. Scale bar = 200 m.</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5167128 Figure_4-F-G</id>
			
		
			<infon key="sourcedata_document">2424</infon>
			
		
			<infon key="doi">10.15252/emmm.201506035</infon>
			
		
			<infon key="pmc_id">5167128</infon>
			
		
			<infon key="figure">Figure 4-F-G</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-F-G</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(F, G) 4-AP treatment increased the number of myelinated axons (**: p=0.002, n=4; ANOVA, with post-hoc comparisons using two-tailed unpaired t-test). Even though the 4-AP treated group also exhibited a greater number of total axons, this difference was not statistically significant. All myelinated and total axons were counted in 5 randomly chosen grids from each of 4 nerves for each group. This experiment represents a single group of mice of one of three replicates on NCV recovery.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:myelinated</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="10" offset="46"/>
					
				
					<text>myelinated</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:myelinated</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="10" offset="288"/>
					
				
					<text>myelinated</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5167128 Figure_5-A-B-C</id>
			
		
			<infon key="sourcedata_document">2424</infon>
			
		
			<infon key="doi">10.15252/emmm.201506035</infon>
			
		
			<infon key="pmc_id">5167128</infon>
			
		
			<infon key="figure">Figure 5-A-B-C</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_5-A-B-C</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) At 1 day post-injury, a single dose of 10 μg 4-AP significantly improved walking function as determined by SFI analysis (*: p=0.001, n=5). (B) In contrast, even higher doses of 4-AP administration (50 μg, ip) had no effect on SFI in mice with transected nerves (n=10). (C) In contrast with effects of 4-AP, treatment with neostigmine did not cause improvements in SFI. (p = 0.0024 for 4-AP vs. saline, n=8, 1-way ANOVA with Tukey's multiple comparison test).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:administration</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="14" offset="187"/>
					
				
					<text>administration</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		

	</collection>
